Acute and subacute ischemic stroke patients Circulatory System
Conditions
Interventions
Eligible patients will be randomly allocated into the EA group or sham EA group. SPSS 26.0 will be used to generate the randomization sequence and allocation ratio. Group allocation data will be conce
Sponsors
Science, Technology and Innovation Commission of Shenzhen Municipality
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A diagnosis of ischemic stroke according to the American Heart Association/American Stroke Association 2. Participants with acute and subacute stroke, the stroke onset within 2 weeks 3. Aged 18 to 80 years old 4. After treatment, symptoms were stable 5. Patients are conscious and are able to finish all examinations and evaluations 6. Patients sign a written informed consent and voluntarily participate in this study
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, lung, liver, and kidney dysfunction 2. Patients with diseases which affect cognitive function assessment, including neurodegenerative diseases, mental illnesses, and others 3. Patients with diseases which affect motor function assessment, including epilepsy, movement disorders, and others 4. Patients with aphasia, severe visual and auditory disorders 5. Patients with brain tumor and craniocerebral injury 6. Long-term using sedatives and antidepressants 7. Patients cannot receive electroacupuncture treatment, due to needle fainting, and cannot cooperate with the researcher for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurological dysfunction assessed using the National Institute of Health stroke scale (NIHSS) at baseline, 24 hours after the first treatment, and weeks 1, 2 and 3 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Neurological function measured using the Fugl-Meyer Assessment (FMA) at baseline and weeks 1, 2 and 3 2. Activity of daily living measured using the Modified Barthel index (MBI) at baseline and weeks 1, 2 and 3 3. Cognitive function measured using the Mini-Mental State Examination (MMSE) at baseline and weeks 1, 2 and 3 4. Transcriptomic sequencing using blood samples collected before the first treatment, 24 hours after the first treatment, and weeks 1, 2 and 3 5. Metabolomic sequencing using blood samples collected before the first treatment, 24 hours after the first treatment, and weeks 1, 2 and 3 | — |
Countries
China
Outcome results
None listed